Other trials have demonstrated that treatment with single-agent inhibitors of the PI3K pathway has only limited efficacy in patients with metastatic breast cancer, whether unselected [10] or selected for the presence of PIK3CA/AKT/PTEN alterations in the tumor [22]. The gene discussed is PTEN; the disease is neoplasm.